Brandon A. Wilbanks

The paper identifies LCK-driven EGFR activation as a therapeutic target in cholangiocarcinoma, showing EGFR activity predicts response to EGFR inhibition.

This study identifies AKT as a regulator of YAP stability and shows that AKT inhibition triggers ESCRT-dependent YAP degradation, enhancing the efficacy of RAS inhibition in pancreatobiliary cancers.

This study explores optimizing aptamer-drug conjugates for GBM treatment by focusing on internalization and tumor homing through in vivo SELEX, but faces challenges with tumor specificity.

This study develops and tests DNA aptamer-drug conjugates (ApDCs) for glioblastoma treatment using an in vivo SELEX approach in a patient-derived xenograft model.

This study uses unbiased cell culture selections to identify DNA aptamers specific to senescent cells, demonstrating their utility as reagents for detecting senescent cells in vitro and in tissues.

The paper demonstrates the feasibility of identifying biologically active DNA aptamers that modulate the activity of human SH-SY5Y neuroblastoma cells.

This paper introduces MODCELL, a modular cell engineering framework validated experimentally to enhance strain design for biochemical production by coupling modular chassis cells with exchangeable production modules.